1. LBA18_PRDurable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). (23rd October 2018) Authors: Lenz, H-J J; Van Cutsem, E; Limon, M L; Wong, K Y; Hendlisz, A; Aglietta, M; Garcia-Alfonso, P; Neyns, B; Luppi, G; Cardin, D; Dragovich, T; Shah, U; Atasoy, A; Postema, R; Boyd, Z; Ledeine, J-M; Overman, M; Lonardi, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗